Table 1.

Clinical trials targeting the PD-L1/PD-1 axis and combinations.

PD-1/PDL-1 clinical trials		Targets	NCT identifier
PD-1/PD-L1 monotherapy		PD-1/PD-L1 axis	NCT03936959, NCT03013101, NCT03167853, NCT03142334, NCT02853344, NCT02702414, NCT02838823, NCT02836795, NCT03010176, NCT03219775, NCT03692442, NCT02358031
Combination therapies with PD-1/PD-L1 blockade	with other immunotherapies	PD-1/PD-L1 axis and CTLA-4, LAG-3, OX40, TIM-3, GITR, CD20 mAbs, IL2R, IL12, IL7R, IL1B, CD19, CD40, CD38, 41BB	NCT03179007, NCT03615313, NCT03190811, NCT03732547, NCT03970382, NCT03527251, NCT03894215, NCT01968109, NCT02658981, NCT03680508, NCT04198766, NCT04215978
	with targeted therapies	PD-1/PD-L1 axis and VEGF/VEGFR, ERK1/2, RAF, AMPK, EGFR, FGFR, MEK, RAF pathways	NCT03851614, NCT04010071, NCT02133742, NCT04152356, NCT03955354, NCT04303741, NCT04014101, NCT03722875, NCT03394287, NCT03359018, NCT02873390, NCT03182816
	with chemotherapy	PD-1/PD-L1 axis and direct cancer cell cytotoxicity	NCT03903887, NCT03311789, NCT03737123, NCT04152889, NCT03041181, NCT03515629, NCT03701607, NCT03409614, NCT04225364, NCT02220894, NCT02819518, NCT03221426
	Other combinations (radiotherapy, chemoradio, multi-way combo, others)	PD-1/PD-L1 axis and direct cancer cell cytotoxicity	NCT02821182, NCT04017897, NCT03898895, NCT03557411, NCT03984357, NCT03671265, NCT03984357, NCT03619824, NCT03474094, NCT02992912, NCT02434081, NCT02525757